Regeneron’s REGEN-COV2 is First Antibody Cocktail for COVID-19 to Receive FDA Emergency Use Authorization

First treatment of any kind to have prospectively confirmed and statistically significant anti-viral activity against SARS-CoV-2

Authorized for recently diagnosed, mild to moderate COVID-19 in high-risk patients

Initial doses of REGEN-COV2 will be made available to approximately 300,000 patients, with no medication out-of-pocket costs, under U.S. government allocation programContinue reading

Banner Health recommends alternatives to in-person gatherings this Thanksgiving

PHOENIX (November 17, 2020) – The United States is experiencing uncontrollable spread of COVID-19, and social gatherings are an important contributor to the rise in COVID-19 cases. Banner Health advises that individuals evaluate the risk level of their Thanksgiving plans and consider safer alternatives for those activities that present a higher risk of contracting or spreading the virus.Continue reading

PhRMA Announces First-Ever, Industry-Wide Principles on Clinical Trial Diversity

“The industry’s new clinical trial diversity principles are an important step toward greater health equity,” said Stephen J. Ubl, president and chief executive officer of PhRMA. “We are addressing issues of mistrust and working to reduce systemic issues that deter communities of color from participating in clinical trials, so that those patients who want to participate, can.”
Continue reading

Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study

  • First interim analysis included 95 participants with confirmed cases of COVID-19
  • Phase 3 study met statistical criteria with a vaccine efficacy of 94.5% (p <0.0001)

Moderna intends to submit for an Emergency Use Authorization (EUA) with U.S. FDA in the coming weeks and expects the EUA to be based on the final analysis of 151 cases and a median follow-up of more than 2 monthsContinue reading

Managing the microbiome raises new hope for autism

In new research appearing in the journal mSphere, Rosa Krajmalnik-Brown, James Adams and their colleagues highlight the crucial importance of bacterial microbes in the human gut for the diagnosis and treatment of ASD. 

In September of 2020, Rosa Krajmalnik-Brown was honored as the Arizona Bioscience Researcher of the Year
Continue reading